Hier fehlt deine Aufmerksamkeit - 500 Beiträge pro Seite
eröffnet am 20.08.09 14:33:40 von
neuester Beitrag 11.03.10 19:08:01 von
neuester Beitrag 11.03.10 19:08:01 von
Beiträge: 18
ID: 1.152.525
ID: 1.152.525
Aufrufe heute: 0
Gesamt: 2.622
Gesamt: 2.622
Aktive User: 0
ISIN: US02155H2004 · WKN: A2N5Z6 · Symbol: 3G0
6,5530
EUR
+2,18 %
+0,1400 EUR
Letzter Kurs 18:01:50 Tradegate
Neuigkeiten
| Titel |
|---|
21.05.24 · Business Wire (engl.)  |
20.05.24 · Business Wire (engl.) |
15.05.24 · Business Wire (engl.) |
14.05.24 · Business Wire (engl.) |
13.05.24 · Business Wire (engl.) |
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,8200 | +34,81 | |
| 1,6699 | +21,89 | |
| 120,18 | +20,00 | |
| 0,5750 | +19,79 | |
| 229,50 | +12,83 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 4,0000 | -20,00 | |
| 0,7018 | -29,81 | |
| 0,7500 | -35,34 | |
| 1,0200 | -41,04 | |
| 2,1000 | -47,50 |
Feedback
Pharmathene hat ein Abkommen mit Medarex, somit auch mit einem big-Player.
Von Vaxgen wurden die Rechte zu einem HIV-Impfstoff abgekauft, der wegen unzureichender Wirkung nicht weiter entwickelt wurde, mit der Technologie von Pharmathene aber möglicherweise doch noch ein Erfolg werden könnte. Darüber hinaus gibt es eine Reihe von Alleanzen und Produkten in er Pipeline.
Mal sehen, ob ich noch genaueres hier reinstelle.
Der Kurs bewegt sich jedenfalls ziemlich weit unten und die Aufmerksamkeit der Anleger ist hier noch nicht angekommen. ....
Von Vaxgen wurden die Rechte zu einem HIV-Impfstoff abgekauft, der wegen unzureichender Wirkung nicht weiter entwickelt wurde, mit der Technologie von Pharmathene aber möglicherweise doch noch ein Erfolg werden könnte. Darüber hinaus gibt es eine Reihe von Alleanzen und Produkten in er Pipeline.
Mal sehen, ob ich noch genaueres hier reinstelle.
Der Kurs bewegt sich jedenfalls ziemlich weit unten und die Aufmerksamkeit der Anleger ist hier noch nicht angekommen. ....
HIV
Impfstoff bleibt Utopie
Seit Jahrzehnten suchen Forscher nach einer Schutzimpfung gegen HIV. Doch der Aids-Erreger erweist sich als trickreich. Noch immer ist weit und breit kein Impfstoff in Sicht.
Vor 25 Jahren wurde im US-Fachjournal „Science“ ein krankmachendes Virus beschrieben, das sich später als der Aids-Erreger HIV herausstellte. Das nährte Hoffnungen auf einen Impfstoff, schließlich haben Mediziner solche Substanzen bereits gegen viele Krankheiten wie Kinderlähmung, Masern, Mumps oder Grippe geschaffen. Am 23. April 1984 erklärte die damalige US-Gesundheitsministerin Margaret Heckler, dass ein solches Präparat binnen zweier Jahre erwartet werden könne. Seither hat das Virus weltweit mehr als 25 Millionen Menschen getötet – und die Aussage der Ministerin zu einem der großen Irrtümer der Medizingeschichte gemacht.
Der Seuchenzug hat in den armen Ländern verheerende Folgen. Weltweit sterben täglich rund 6000 Menschen. „Die ernüchternde Wahrheit ist, dass es derzeit keinen aussichtsreichen Kandidaten für einen HIV-Impfstoff gibt“, schreibt Bruce Walker von der Harvard Medical School in Boston (Massachusetts) ein Vierteljahrhundert nach der HIV-Entdeckung in „Science“ (Bd. 320, S. 760).
Gestoppte Tests
Seine Analyse zeigt, dass der Mensch derzeit weit davon entfernt ist, Hilfe zu finden. Auch auf der Welt-Aids-Konferenz in Mexiko-Stadt (3. bis 8. August) ist nicht mit der Verkündung großer Fortschritte zu rechnen. Im Gegenteil: Kurz vor deren Beginn stoppte der Direktor des US-Instituts für Infektionskrankheiten, Anthony Fauci, einen geplanten neuen Impfstofftest – mangels Erfolgsaussichten. Die Forscher müssten im Labor zunächst mehr über das Virus lernen, sagte Fauci.
Die Hoffnung auf einen Impfstoff hatte bereits Ende 2007 einen heftigen Tiefschlag erlitten. Damals wurde ein Test abgebrochen, weil das Präparat des US-Pharmakonzerns Merck & Co. das Risiko einer Infektion scheinbar sogar erhöhte. In der Folge kamen bei führenden Experten grundsätzliche Zweifel auf: „Um brutal ehrlich mit uns selbst zu sein, müssen wir der Möglichkeit ins Auge sehen, dass wir niemals einen Impfstoff gegen HIV finden könnten“, erklärte Fauci damals. Doch man gebe nicht auf, betonte der oberste Aids-Bekämpfer der USA im „New England Journal of Medicine“ (Bd. 357, S. 2653).
Barriere für Erreger
Wünschenswert wäre eine Immunbarriere, die die Infektion verhindert, das Virus also gar nicht erst in die Zelle lässt. Falls dies scheitert, sollte zumindest seine Vermehrung gehemmt werden. Die Haupttorwächter des Immunsystems sind die Antikörper, Moleküle, die in großer Zahl im Blut enthalten sind. Sie entstehen, wenn Immunzellen Eindringlinge erkennen und die passenden Antikörper dagegen konstruieren. Diese Moleküle erkennen den Fremdkörper, lagern sich an und verhindern die Infektion der Zellen. Nach diesem Prinzip wurden Impfstoffe gegen zahlreiche Krankheitserreger hergestellt. Diese funktionieren aber nur dann gut, wenn sich der Erreger nicht oder nur wenig wandelt – aber genau dies tut HIV besonders häufig.
Gestiegene Lebenserwartung
Medikamente können Ausbruch und Verlauf der Immunschwäche nur verzögern. Immerhin ist die Lebenserwartung von HIV-Infizierten in den vergangenen Jahren durch Kombinationstherapien gestiegen, von 1996 bis 2005 um 13 Jahre, berichten Forscher im Journal „The Lancet“ (Bd. 372, S. 293). Das gilt jedoch nur für die reichen Industrieländer. Die Staatengemeinschaft ist indes weit davon entfernt, ihre selbst gesteckten Ziele bei der Versorgung der Patienten mit Medikamenten zu erreichen: Ende 2007 erhielten 31 Prozent der 9,7 Millionen Bedürftigen die Pillen. „Das bedeutet, dass etwa 6,7 Millionen keinen Zugang zu den lebensrettenden Medikamenten haben“, heißt es in einem gemeinsamen Bericht des Aids-Programms der Vereinten Nationen (UNAIDS), der Weltgesundheitsorganisation (WHO) und des UN- Kinderhilfswerks UNICEF von Anfang Juni.
Beschneidung senkt Infektionsrate
Einige Experten kritisieren, dass bei der Verteilung des Geldes im Kampf gegen Aids mitunter falsche Prioritäten gesetzt werden. So hat sich etwa in mehr als 40 Untersuchungen gezeigt, dass die Beschneidung von Männern deren Risiko einer heterosexuellen Infektion reduzieren kann. Die konsequente Beschneidung könne in den nächsten 20 Jahren in den Ländern südlich der Sahara, wo die Immunschwäche besonders grassiert, 5,7 Millionen neue Infektionen und 3 Millionen Todesfälle verhindern, betont etwa eine Gruppe von zehn Experten der Universitäten Harvard und von Kalifornien. Aber nur ein Prozent des weltweit gegen Aids ausgegebenen Geldes werde in diesem Bereich verwendet. Sicheren Schutz bietet das Verfahren allerdings ohnehin nicht – das Infektionsrisiko sinkt lediglich auf etwas weniger als die Hälfte.
cf/dpa
http://www.focus.de/gesundheit/ratgeber/zukunftsmedizin/news…" target="_blank" rel="nofollow ugc noopener">http://www.focus.de/gesundheit/ratgeber/zukunftsmedizin/news…
Waren die Test, die im oberen Artikel genannt wurden, von deiner Gesellschaft?
Moin und gruezi,
befasse mich nicht direkt mit der Infektion und deren Heilung, habe eher an einer anderen Aktien ein schon länger bestehendes Interesse. Dort geht es aber mehr um die schnelle Erkennung, als mit der Heilung. Nach einigen Recherchen habe ich festgestellt , das der HIV/AIDS Virus einer der wenigen "intelligenten" Viren ist, dem der Mensch fast schutzlos ausgeliefert ist. Wir haben noch nicht mal die aller erste Generation der Viren verstanden und könnten sie nicht ansatzweise bekämpfen. Seit den ersten Fällen in den 80. Jahren, die dem Virus direkt zugeordnet werden konnten, hat das Drecksding sich zich mal verändert und ist mutiert. Eine kleine Veränderung der beteiligten Faktoren, kann ein erst ganz gutes Mittel, was in den Test gut abschneidet, sofort bewirken, das sich der Virus anpasst und mutiert. Man war sich mit den HIV1 und 2 Viren erst sehr sicher, das sie vom Schimpansen zum Menschen überspringen, sich dann mit den Zellen verbinden und ihren Feldzug dann starten. Diese Kette ist die Grundlage der Forscher. Das hat der Virus sich gemerkt. Vor kurzem wurde ein neuer Stamm entdeckt, der weitere Komponenten ins Spiel bringt. Der Virus nimmt den Umweg über Gorillas. Damit hat er zwar den HIV 1 und 2 Stamm, aber mutiert dann fast zu einer neuen Krankheit. Abgesehen von der Verbreitung durch Menschen, wie auch immer, war bisher die Keimzelle in der Nähe von Schimpansen zu suchen. Der neue mutierte Stamm der die Struktur von dem Urvirus bei Schimpansen und Gorillas hat braucht keine Nähe von den Tieren zum Mensch. Der neue Stamm wurde vor kurzem in Afrika bei einer Frau entdeckt Diese Frau führte ein friedliches Leben, also keine Vergewaltigungen etc.... keine Affen in der Nähe und hatte auch kein ärmliches Leben, wo die Ansteckungsrate deutlich höher ist.
Der neue Stamm hat einen Weg gefunden sich zu verbreiten, ohne das Wissenschaftler die genauen Wege des Virus nach vollziehen können.
Anfang des Jahres keimte die Hoffnung aber wieder auf, das war aber VOR der aktuellen Mutationswelle. Die EU finanzierte ein Projekt das einen Gen-basierten Impfstoff gegen HIV hervorbringen sollte, die gezielt von Dendritischen Zellen aufgenommen werden soll. Die Dendritischen Zellen spielen eine wichtige Rolle bei der Bildung antiviraler Immunantworten. Die Studie sollte die besten Wege für Immunantworten am Eintrittsort von HIV in den exponierten Schleimhäuten hervorbringen. Zusätzlich sollte auch eine Immunantwort gegen das Viruspartikel von HIV gefunden werden und wie es reguliert wird. In etwa will man herrausfinden warum unser Immusystem das Drecksding nicht erkennt.
Um nicht völlig vor der Krankheit zu resignieren gibt es wohl nur noch einen wirklich möglichen Weg dem Virus auf die Schliche zu kommen.
Die Entwicklung von Impfstoffen, die Antikörperantworten induzieren, die stammübergreifend verschiedene HIV-Versionen aus schaltet. Die große Wandelbarkeit der Hülle des HIV Virus macht dies ast unmöglich.
Das einzige was vielleicht noch funktionieren könnte ist die einzige Schwachstelle des Virus. Gewisse Stellen in der Struktur verändern sich so gut wie nie, egal welcher Stamm und welcher Überträger.. Mensch, Gorilla, Schimpanse, Bonobo.
Hat der Versuch deiner AG diesen Weg untersucht, wenn nicht, macht dir keine Hoffnung, das es was wird.
Unter Umständen wird in den nächsten jahren ein Mittel bzw eine Lösung gefunden um die Viren kurzfristig bei der EIndringung in die Schleimhäute zu abzutöten. Es könnten Cremes oder ähnliches entwickelt werden, die vorher auf die Schleimhäute aufgetragen werden. Nun belibt es deiner Phantasie überlassen, welche Ansteckungswege so nicht verhindert werden können.
Einige Labors werkeln auch an einem Hammer für die Zellen des menschlichen Körpers. Kurz nach einer möglichen Ansteckung soll so ein Mittel auf den Markt gebracht werden was die betreffenden Personen oral einnehmen müssen, die möglichen Folgen für die normalen nicht gefährlichen Viren und Zellen im Körper kann aber zur Zeit noch nicht erahnt werden.
Die Probleme die der Mensch hat ist, das ausgerechnet der HIV Virus nur bei menschlichen Zellen zu AIDS führt und seine tödliche Wirkung entfaltet. Also keine Tests mit Tieren etc....
Kurz gesagt alle Labors und Gesellschaften die sich mit den oben genanten Varianten befassen haben die minimale Möglichkeit Erfolge zu erzielen. Alles andere ist Geldverschwendung. Der Virus verändert sich zu schnell. Von Generation zu Generation kann der Virus seine komplette Struktur verändern. Meist wenn er gezwungen wird, das zu tun, das der Mensch auch wenn er genug Geld hat, da hinterher kommt, ist aktuell Utopie. Ich würde sagen, dass bevor der Mensch sich selbst nicht fehlerfrei Klonen kann Aufgrund der dafür nötigen Kenntnisse), keine wirksamen Mittel gefunden werden. Einige Mittel greifen nicht nur den HIV Virus an, sondern gleich andere Zellen, die in der Nähe von Schleimhäuten sich befinden. Im best Case wird der HIV Virus eingedämmt, aber gleichzeitig mutiert deine Lunge und führt z.B. zu schlimmsten Infektionen und Reizungen die man dann auch nicht mehr behandeln kann.
Bei der Aktien würde ich die AIDS/HIV Phantasie ausklammern und auf die anderen Mittel den Schwerpunkt legen. z.B. die beiden Antrax Mittel.
Welche anderen Mittel hat die AG noch in der Pipeline? Wie sehen die Verkaufszahlen aus? Wie die Vertriebswege? Stehen Umsatzsteigerungen an?
gruß
Impfstoff bleibt Utopie
Seit Jahrzehnten suchen Forscher nach einer Schutzimpfung gegen HIV. Doch der Aids-Erreger erweist sich als trickreich. Noch immer ist weit und breit kein Impfstoff in Sicht.
Vor 25 Jahren wurde im US-Fachjournal „Science“ ein krankmachendes Virus beschrieben, das sich später als der Aids-Erreger HIV herausstellte. Das nährte Hoffnungen auf einen Impfstoff, schließlich haben Mediziner solche Substanzen bereits gegen viele Krankheiten wie Kinderlähmung, Masern, Mumps oder Grippe geschaffen. Am 23. April 1984 erklärte die damalige US-Gesundheitsministerin Margaret Heckler, dass ein solches Präparat binnen zweier Jahre erwartet werden könne. Seither hat das Virus weltweit mehr als 25 Millionen Menschen getötet – und die Aussage der Ministerin zu einem der großen Irrtümer der Medizingeschichte gemacht.
Der Seuchenzug hat in den armen Ländern verheerende Folgen. Weltweit sterben täglich rund 6000 Menschen. „Die ernüchternde Wahrheit ist, dass es derzeit keinen aussichtsreichen Kandidaten für einen HIV-Impfstoff gibt“, schreibt Bruce Walker von der Harvard Medical School in Boston (Massachusetts) ein Vierteljahrhundert nach der HIV-Entdeckung in „Science“ (Bd. 320, S. 760).
Gestoppte Tests
Seine Analyse zeigt, dass der Mensch derzeit weit davon entfernt ist, Hilfe zu finden. Auch auf der Welt-Aids-Konferenz in Mexiko-Stadt (3. bis 8. August) ist nicht mit der Verkündung großer Fortschritte zu rechnen. Im Gegenteil: Kurz vor deren Beginn stoppte der Direktor des US-Instituts für Infektionskrankheiten, Anthony Fauci, einen geplanten neuen Impfstofftest – mangels Erfolgsaussichten. Die Forscher müssten im Labor zunächst mehr über das Virus lernen, sagte Fauci.
Die Hoffnung auf einen Impfstoff hatte bereits Ende 2007 einen heftigen Tiefschlag erlitten. Damals wurde ein Test abgebrochen, weil das Präparat des US-Pharmakonzerns Merck & Co. das Risiko einer Infektion scheinbar sogar erhöhte. In der Folge kamen bei führenden Experten grundsätzliche Zweifel auf: „Um brutal ehrlich mit uns selbst zu sein, müssen wir der Möglichkeit ins Auge sehen, dass wir niemals einen Impfstoff gegen HIV finden könnten“, erklärte Fauci damals. Doch man gebe nicht auf, betonte der oberste Aids-Bekämpfer der USA im „New England Journal of Medicine“ (Bd. 357, S. 2653).
Barriere für Erreger
Wünschenswert wäre eine Immunbarriere, die die Infektion verhindert, das Virus also gar nicht erst in die Zelle lässt. Falls dies scheitert, sollte zumindest seine Vermehrung gehemmt werden. Die Haupttorwächter des Immunsystems sind die Antikörper, Moleküle, die in großer Zahl im Blut enthalten sind. Sie entstehen, wenn Immunzellen Eindringlinge erkennen und die passenden Antikörper dagegen konstruieren. Diese Moleküle erkennen den Fremdkörper, lagern sich an und verhindern die Infektion der Zellen. Nach diesem Prinzip wurden Impfstoffe gegen zahlreiche Krankheitserreger hergestellt. Diese funktionieren aber nur dann gut, wenn sich der Erreger nicht oder nur wenig wandelt – aber genau dies tut HIV besonders häufig.
Gestiegene Lebenserwartung
Medikamente können Ausbruch und Verlauf der Immunschwäche nur verzögern. Immerhin ist die Lebenserwartung von HIV-Infizierten in den vergangenen Jahren durch Kombinationstherapien gestiegen, von 1996 bis 2005 um 13 Jahre, berichten Forscher im Journal „The Lancet“ (Bd. 372, S. 293). Das gilt jedoch nur für die reichen Industrieländer. Die Staatengemeinschaft ist indes weit davon entfernt, ihre selbst gesteckten Ziele bei der Versorgung der Patienten mit Medikamenten zu erreichen: Ende 2007 erhielten 31 Prozent der 9,7 Millionen Bedürftigen die Pillen. „Das bedeutet, dass etwa 6,7 Millionen keinen Zugang zu den lebensrettenden Medikamenten haben“, heißt es in einem gemeinsamen Bericht des Aids-Programms der Vereinten Nationen (UNAIDS), der Weltgesundheitsorganisation (WHO) und des UN- Kinderhilfswerks UNICEF von Anfang Juni.
Beschneidung senkt Infektionsrate
Einige Experten kritisieren, dass bei der Verteilung des Geldes im Kampf gegen Aids mitunter falsche Prioritäten gesetzt werden. So hat sich etwa in mehr als 40 Untersuchungen gezeigt, dass die Beschneidung von Männern deren Risiko einer heterosexuellen Infektion reduzieren kann. Die konsequente Beschneidung könne in den nächsten 20 Jahren in den Ländern südlich der Sahara, wo die Immunschwäche besonders grassiert, 5,7 Millionen neue Infektionen und 3 Millionen Todesfälle verhindern, betont etwa eine Gruppe von zehn Experten der Universitäten Harvard und von Kalifornien. Aber nur ein Prozent des weltweit gegen Aids ausgegebenen Geldes werde in diesem Bereich verwendet. Sicheren Schutz bietet das Verfahren allerdings ohnehin nicht – das Infektionsrisiko sinkt lediglich auf etwas weniger als die Hälfte.
cf/dpa
http://www.focus.de/gesundheit/ratgeber/zukunftsmedizin/news…" target="_blank" rel="nofollow ugc noopener">http://www.focus.de/gesundheit/ratgeber/zukunftsmedizin/news…
Waren die Test, die im oberen Artikel genannt wurden, von deiner Gesellschaft?
Moin und gruezi,
befasse mich nicht direkt mit der Infektion und deren Heilung, habe eher an einer anderen Aktien ein schon länger bestehendes Interesse. Dort geht es aber mehr um die schnelle Erkennung, als mit der Heilung. Nach einigen Recherchen habe ich festgestellt , das der HIV/AIDS Virus einer der wenigen "intelligenten" Viren ist, dem der Mensch fast schutzlos ausgeliefert ist. Wir haben noch nicht mal die aller erste Generation der Viren verstanden und könnten sie nicht ansatzweise bekämpfen. Seit den ersten Fällen in den 80. Jahren, die dem Virus direkt zugeordnet werden konnten, hat das Drecksding sich zich mal verändert und ist mutiert. Eine kleine Veränderung der beteiligten Faktoren, kann ein erst ganz gutes Mittel, was in den Test gut abschneidet, sofort bewirken, das sich der Virus anpasst und mutiert. Man war sich mit den HIV1 und 2 Viren erst sehr sicher, das sie vom Schimpansen zum Menschen überspringen, sich dann mit den Zellen verbinden und ihren Feldzug dann starten. Diese Kette ist die Grundlage der Forscher. Das hat der Virus sich gemerkt. Vor kurzem wurde ein neuer Stamm entdeckt, der weitere Komponenten ins Spiel bringt. Der Virus nimmt den Umweg über Gorillas. Damit hat er zwar den HIV 1 und 2 Stamm, aber mutiert dann fast zu einer neuen Krankheit. Abgesehen von der Verbreitung durch Menschen, wie auch immer, war bisher die Keimzelle in der Nähe von Schimpansen zu suchen. Der neue mutierte Stamm der die Struktur von dem Urvirus bei Schimpansen und Gorillas hat braucht keine Nähe von den Tieren zum Mensch. Der neue Stamm wurde vor kurzem in Afrika bei einer Frau entdeckt Diese Frau führte ein friedliches Leben, also keine Vergewaltigungen etc.... keine Affen in der Nähe und hatte auch kein ärmliches Leben, wo die Ansteckungsrate deutlich höher ist.
Der neue Stamm hat einen Weg gefunden sich zu verbreiten, ohne das Wissenschaftler die genauen Wege des Virus nach vollziehen können.
Anfang des Jahres keimte die Hoffnung aber wieder auf, das war aber VOR der aktuellen Mutationswelle. Die EU finanzierte ein Projekt das einen Gen-basierten Impfstoff gegen HIV hervorbringen sollte, die gezielt von Dendritischen Zellen aufgenommen werden soll. Die Dendritischen Zellen spielen eine wichtige Rolle bei der Bildung antiviraler Immunantworten. Die Studie sollte die besten Wege für Immunantworten am Eintrittsort von HIV in den exponierten Schleimhäuten hervorbringen. Zusätzlich sollte auch eine Immunantwort gegen das Viruspartikel von HIV gefunden werden und wie es reguliert wird. In etwa will man herrausfinden warum unser Immusystem das Drecksding nicht erkennt.
Um nicht völlig vor der Krankheit zu resignieren gibt es wohl nur noch einen wirklich möglichen Weg dem Virus auf die Schliche zu kommen.
Die Entwicklung von Impfstoffen, die Antikörperantworten induzieren, die stammübergreifend verschiedene HIV-Versionen aus schaltet. Die große Wandelbarkeit der Hülle des HIV Virus macht dies ast unmöglich.
Das einzige was vielleicht noch funktionieren könnte ist die einzige Schwachstelle des Virus. Gewisse Stellen in der Struktur verändern sich so gut wie nie, egal welcher Stamm und welcher Überträger.. Mensch, Gorilla, Schimpanse, Bonobo.
Hat der Versuch deiner AG diesen Weg untersucht, wenn nicht, macht dir keine Hoffnung, das es was wird.
Unter Umständen wird in den nächsten jahren ein Mittel bzw eine Lösung gefunden um die Viren kurzfristig bei der EIndringung in die Schleimhäute zu abzutöten. Es könnten Cremes oder ähnliches entwickelt werden, die vorher auf die Schleimhäute aufgetragen werden. Nun belibt es deiner Phantasie überlassen, welche Ansteckungswege so nicht verhindert werden können.
Einige Labors werkeln auch an einem Hammer für die Zellen des menschlichen Körpers. Kurz nach einer möglichen Ansteckung soll so ein Mittel auf den Markt gebracht werden was die betreffenden Personen oral einnehmen müssen, die möglichen Folgen für die normalen nicht gefährlichen Viren und Zellen im Körper kann aber zur Zeit noch nicht erahnt werden.
Die Probleme die der Mensch hat ist, das ausgerechnet der HIV Virus nur bei menschlichen Zellen zu AIDS führt und seine tödliche Wirkung entfaltet. Also keine Tests mit Tieren etc....
Kurz gesagt alle Labors und Gesellschaften die sich mit den oben genanten Varianten befassen haben die minimale Möglichkeit Erfolge zu erzielen. Alles andere ist Geldverschwendung. Der Virus verändert sich zu schnell. Von Generation zu Generation kann der Virus seine komplette Struktur verändern. Meist wenn er gezwungen wird, das zu tun, das der Mensch auch wenn er genug Geld hat, da hinterher kommt, ist aktuell Utopie. Ich würde sagen, dass bevor der Mensch sich selbst nicht fehlerfrei Klonen kann Aufgrund der dafür nötigen Kenntnisse), keine wirksamen Mittel gefunden werden. Einige Mittel greifen nicht nur den HIV Virus an, sondern gleich andere Zellen, die in der Nähe von Schleimhäuten sich befinden. Im best Case wird der HIV Virus eingedämmt, aber gleichzeitig mutiert deine Lunge und führt z.B. zu schlimmsten Infektionen und Reizungen die man dann auch nicht mehr behandeln kann.
Bei der Aktien würde ich die AIDS/HIV Phantasie ausklammern und auf die anderen Mittel den Schwerpunkt legen. z.B. die beiden Antrax Mittel.
Welche anderen Mittel hat die AG noch in der Pipeline? Wie sehen die Verkaufszahlen aus? Wie die Vertriebswege? Stehen Umsatzsteigerungen an?
gruß
Antwort auf Beitrag Nr.: 37.821.839 von stargold123 am 20.08.09 22:00:01Um es kurz zu machen, dass mit dem HIV-Impfstoff, der ja noch nicht zuende entwickelt ist, war nur ein Schmankerl.
Die Firma hat sich auf die Vverteidigung von Bioterrorismus spezialisiert und frühzeitig die Kommerziale Nutzung darüber hinaus fokussiert.
http://www.pharmathene.com/
Zum HIV wäre noch hoch interessant anzumerken, dass es Personen gibt, die eine natürliche Immunität gegen diesen Virus haben und das bereits geforscht wird, worin der Trick besteht. Leider ist mir nicht bekannt, wer da mit wem zusammen forscht, sonst hätte ich mich da schon eingekauft.
Die Firma hat sich auf die Vverteidigung von Bioterrorismus spezialisiert und frühzeitig die Kommerziale Nutzung darüber hinaus fokussiert.
http://www.pharmathene.com/
Zum HIV wäre noch hoch interessant anzumerken, dass es Personen gibt, die eine natürliche Immunität gegen diesen Virus haben und das bereits geforscht wird, worin der Trick besteht. Leider ist mir nicht bekannt, wer da mit wem zusammen forscht, sonst hätte ich mich da schon eingekauft.
freue mich, dass seit meiner ersten Notiz hier schon über 25% Gewinn sind 
kleine Verschnaufpause, kann durchaus noch 20-30 Cent runter gehen, dann kaufe ich nach!
Trading Spotlight
Also, das war 2007 im Sept.:
Institutes of Health announced a contract with Maryland-based PharmAthene Inc. partnering with Medarex Inc. to develop an anthrax therapy.
PharmAthene develops medical countermeasures against biological and chemical threats for biodefense. Together with New Jersey-based Medarex, a leading monoclonal antibody company, it received an up to $13.9 million contract from the National Institute of Allergy and Infectious Diseases and the Biomedical Advanced Research and Development Authority, part of the NIH, for the development of Valortim.
Institutes of Health announced a contract with Maryland-based PharmAthene Inc. partnering with Medarex Inc. to develop an anthrax therapy.
PharmAthene develops medical countermeasures against biological and chemical threats for biodefense. Together with New Jersey-based Medarex, a leading monoclonal antibody company, it received an up to $13.9 million contract from the National Institute of Allergy and Infectious Diseases and the Biomedical Advanced Research and Development Authority, part of the NIH, for the development of Valortim.
hier noch ein paar konkretere Infos
•Pharmathene, Inc. agreements
Manufacturing And Marketing License Agreement
Parties: Pharmathene
Sectors: Financial Services
PharmAthene, Inc.
Confidential Materials Omitted and Filed Separately with the
Securities and Exchange Commission
Confidential Portions denoted by [***]
PRIVATE BETWEEN THE PARTIES
AMENDED AND RESTATED
MANUFACTURING AND MARKETING LICENSE AGREEMENT
between
THE SECRETARY OF STATE FOR DEFENCE
as represented by
THE DEFENCE SCIENCE AND TECHNOLOGY LABORATORY (Dstl)
and
PHARMATHENE UK LTD.
in respect of
RECOMBINANT [***] VACCINE
PRIVATE BETWEEN THE PARTIES
THIS AMENDED AND RESTATED AGREEMENT is made the 11 th day of February, 2009
BETWEEN
THE SECRETARY OF STATE FOR DEFENCE acting through the Defence Science and Technology Laboratory [***] (hereinafter referred to as the " Licensor " ) of the one part
AND
PHARMATHENE UK LTD. Having an address at Johnson Mathey Building, PO Box 88, Haverton Hill Road, Billingham, Cleveland TS23 1XN (hereinafter referred to as the " Licensee " ) of the second part
hereinafter referred to collectively as the " Parties " or in the singular as a " Party " .
WHEREAS
A . The Licensor and Avecia Limited entered into a Manufacturing and Marketing License Agreement as of December 4, 2006, (the "License Agreement");
B. With the consent of the Licensor, the License Agreement was assigned by Avecia Limited to Avecia Biologics Limited;
C. The License Agreement was amended by a Letter Agreement dated March 20, 2008 by and between Licensor and Avecia Biologics Limited (the "Amended Agreement");
D. With the consent of the Licensor, Avecia Biologics Limited assigned the Amended Agreement to the Licensee; and
E. The Licensor and the Licensee desire to amend and restate the Amended Agreement.
NOW IT IS HEREBY AGREED BETWEEN THE PARTIES AS FOLLOWS:-
1. DEFINITIONS AND INTERPRETATION
1.1. For the purposes of this Agreement, unless the context clearly or necessarily indicates otherwise, the following words and phrases shall have the meanings set forth below:
1.1.1. "Agreement" shall mean this Amended and Restated Agreement.
1.1.2. "[***] Vaccine" shall mean [***] which is produced using recombinant technology.
1.1.3. "[***] Vaccine Dose" shall mean the quantity of a formulation containing [***] Vaccine given to an individual in a single immunisation.
1.1.4. "Commencement Date" shall mean the day and year first above written.
1.1.5. "The Intellectual Property" shall mean the Patents and know-how, technical information and materials (including but not limited to cell lines) owned by the Licensor necessary or useful to develop,
PRIVATE BETWEEN THE PARTIES
manufacture, have manufactured, import use, keep, sell and offer to sell the [***] Vaccine and the [***] Vaccine Dose.
1.1.6. "Licensed Product" shall mean [***] Vaccine Dose the manufacture, use, sale, keeping, importing or exporting of which would, in the absence of the licence granted under this Agreement, constitute an infringement of the Patents (for the avoidance of doubt, where the definition of Patents includes pending patent applications, this includes doing anything in respect of a claim in a pending patent application that had a patent been granted on such a claim would constitute infringement of that claim) or that uses other Intellectual Property.
1.1.7. "Net Sales Price" shall mean the actual sale price for Licensed Product invoiced by the Licensee or, where applicable, a Partner of the Licensee less any separate charges identified for packaging, transportation, insurance and sales taxes and (where applicable) any royalties paid to any Third Party in respect of the Licensed Product in question. If the Licensee sells or disposes of any Licensed Product on otherwise than an arms length transaction basis at the open full market price (eg to another company in the Licensee92s group or under an off-set or barter agreement), the open market price shall be taken as the actual sales price.
1.1.8. "PIL" shall mean [***].
1.1.9. "Patents" The patents and patent applications set out in Schedule 1 and any equivalents thereof, and any divisionals, continuations, continuations-in-part, re-filings or re-issues of any of the foregoing, and any other patent applications or patents that would be infringed by manufacture, use or sale of an [***] Vaccine or component thereof.
1.1.10. "Partner" shall mean any Third Party organisation which the Licensee elects to involve in the performance of a Supply Contract.
1.1.11. "Third Party" shall mean any person other than the Government of the United Kingdom.
1.2. The singular shall include the plural and vice versa, and the masculine shall include the feminine or the neuter gender and vice versa.
1.3. Unless the context otherwise indicates, references to Articles and Articles and Schedule, are to articles and Articles and the Schedule of this Agreement.
1.4. Headings to Articles in this Agreement are included for ease of reference only and shall not have any effect on the construction or the interpretation of this Agreement.
1.5. References in this Agreement to any statute or statutory provision shall include any statute or statutory provision which amends, extends, consolidates or replaces the same and shall include any orders, regulations, instruments or other subordinate legislation made under the relevant statute.
PRIVATE BETWEEN THE PARTIES
2. GRANT OF RIGHTS BY THE LICENSOR
2.1. In consideration for the payments to be made by the Licensee to the Licensor under the provisions of Article 3 below, the Licensor, warranting that he has the right to do so, hereby grants and the Licensee hereby accepts a nonexclusive worldwide licence to use the Intellectual Property (i) to develop, make, or have made, use, keep, sell, offer to sell, import and export Licensed Products, and (ii) to develop, make, have made, and use [***] Vaccine for the purpose of Licensor exercising the rights and licenses granted to Licensor with respect to Licensed Product.
2.2. Without prejudice to the provisions of Articles 2.3 and 10.3 below, the Licensor undertakes that it shall not whilst this license remains in effect grant a license to any third party for under the Intellectual Property to make, have made, use, keep, import, export, sell or offer to sell Licensed Products or [***] Vaccine.
2.3. For the avoidance of any doubt, the Licensor and any other Department or Agency of the UK Government shall retain the right at any time to use, or authorise others to use the Licensed Products for any UK Government purpose or otherwise to the extent customary pursuant to standard UK Ministry of Defence contracting procedures, and to dispose of products made in consequence of such use but no longer required; and nothing in this Agreement shall be construed as in any way limiting or derogating from such retained rights, nor from any rights of the Crown arising under any other agreement or contract or provision of law.
2.4. Save as permitted under Article 2.5 below, the licence granted under this Agreement is personal to the Licensee and as such shall not be assigned, sub-licensed, mortgaged or in any way dealt with by the Licensee without the prior written consent of the Licensor, which consent shall not be unreasonably withheld, provided that the Licensee may assign the licence and this Agreement without consent in connection with a genuine business reorganisation or to any corporation, association or other business entity which directly or indirectly controls, is controlled by or is under common control with the Licensee. For the avoidance of doubt, consent shall be deemed to be reasonably withheld where the Chief Executive of Dstl receives written notice from an appropriate authority at the Ministry of Defence or other UK Government Department that assignment to such person would damage the essential public or national interest. Any assignment, sub-licensing or mortgaging of this Agreement by the Licensee, otherwise than as permitted by this Article 2.4, without the prior written consent of the Licensor shall immediately invalidate this Agreement and the license granted hereunder.
2.5. Notwithstanding the provisions of Article 2.4 above, the Licensee shall be entitled to employ Partners to assist the Licensee in exercising the Licensee92s rights hereunder with respect to Licensed Products subject to the provisions of Article 3 below.
2.6. Save as expressly stated under this Article 2 the Licensee is not authorised hereunder to grant to any Third Party any sub-license under the Patents or to pass to such Third Party any of the Intellectual Property.
PRIVATE BETWEEN THE PARTIES
3. LICENCE PAYMENTS
3.1. In consideration for the grant of rights by the Licensor in Article 2.1 above; the Licensee shall pay to the Licensor a royalty on each and every Licensed Product, equal to [***] of the Net Sales Price of the Licensed Product. Notwithstanding the foregoing, no royalties shall be payable in respect of any samples of Licensed Products which are provided by the Licensee for clinical, product development, marketing development or bona fide study purposes. No royalties are payable in respect of supplies of Licensed Products to the UK Ministry of Defence.
3.2. The royalty in respect of a Licensed Product shall become payable by the Licensee under this Agreement when the cost of the Licensed Product is invoiced by Licensee. Where the cost of a Licensed Product is payable in two or more installments, the invoice for each installment will be considered separately for the payment of royalties. If no invoice is issued, royalty will become due on delivery of the Licensed Product concerned.
3.3. The Licensee shall reimburse Licensor for the cost and expense incurred by Licensor after the date of this Agreement for prosecuting and maintaining Patents licensed to Licensee under this Agreement. Should the Licensor wish to abandon a patent, patent application or equivalent forming part of the Intellectual Property, it shall offer it to the Licensee, which shall be entitled to maintain in force the said patent, patent application or equivalent in the name of Licensor at the Licensee92s expense but otherwise without charge and, the Licensee shall be responsible for all further expenditure thereon. The Licensee shall retain a royalty free non-exclusive license thereto pursuant to Section 2.1 that is subject to Licensor92s obligations under Section 2.2.
3.4. The payments due under Articles 3.1 and 3.3 of this Agreement will fall due half-yearly on 30 June and 31 December and will be payable in accordance with the instructions contained in Articles 3.6 and 3.7 below.
3.5. The Licensor has appointed PIL as its agent to act on its behalf for the administration of royalties and other moneys due under this Agreement. .
3.6. Within sixty (60) days of the end of each half-year period as mentioned in Article 3.4 hereof, the Licensee shall send to PIL (or as otherwise advised) a true and complete statement in writing, including where appropriate a Zero return, of the number of Licensed Products manufactured and sold by or for Licensee during the relevant period, the Net Sales Price derived from sales of such Licensed Products, and the royalty calculated to be payable in respect thereof in accordance with the provisions of Article 3.1.
3.7. All payments due to the Licensor under this Agreement shall be made by the end of the month following the month of the date of receipt of an invoice from PIL and in accordance with the instructions issued with the relevant invoice. All royalty statements, correspondence and payments to PIL under the provisions of this Article 3 shall quote the PIL reference [***].
3.8. All payments due to PIL shall be paid in pounds Sterling plus, if applicable, VAT at the UK rate prevailing at the time of payment. Where a payment due is in a currency other than pounds Sterling, the rate of exchange to be applied shall be the rate of exchange applied by the Bank of England on the d ...
*End of Preview*
Click the 'Add to Cart' button to download the complete and formatted agreement.
Agreement#: AG-658261
Pages: 51 pages
Format: MS Word Compatible
Price: $35.00
Add To Cart View other agreements from Pharmathene, Inc. agreements
Healthcare Acquisition - Promissory Note
Healthcare Acquisition - Investment Management Agreement
. Privacy Policy Terms of Service
© Copyright TechAgreements L.L.C. 2007
•Pharmathene, Inc. agreements
Manufacturing And Marketing License Agreement
Parties: Pharmathene
Sectors: Financial Services
PharmAthene, Inc.
Confidential Materials Omitted and Filed Separately with the
Securities and Exchange Commission
Confidential Portions denoted by [***]
PRIVATE BETWEEN THE PARTIES
AMENDED AND RESTATED
MANUFACTURING AND MARKETING LICENSE AGREEMENT
between
THE SECRETARY OF STATE FOR DEFENCE
as represented by
THE DEFENCE SCIENCE AND TECHNOLOGY LABORATORY (Dstl)
and
PHARMATHENE UK LTD.
in respect of
RECOMBINANT [***] VACCINE
PRIVATE BETWEEN THE PARTIES
THIS AMENDED AND RESTATED AGREEMENT is made the 11 th day of February, 2009
BETWEEN
THE SECRETARY OF STATE FOR DEFENCE acting through the Defence Science and Technology Laboratory [***] (hereinafter referred to as the " Licensor " ) of the one part
AND
PHARMATHENE UK LTD. Having an address at Johnson Mathey Building, PO Box 88, Haverton Hill Road, Billingham, Cleveland TS23 1XN (hereinafter referred to as the " Licensee " ) of the second part
hereinafter referred to collectively as the " Parties " or in the singular as a " Party " .
WHEREAS
A . The Licensor and Avecia Limited entered into a Manufacturing and Marketing License Agreement as of December 4, 2006, (the "License Agreement");
B. With the consent of the Licensor, the License Agreement was assigned by Avecia Limited to Avecia Biologics Limited;
C. The License Agreement was amended by a Letter Agreement dated March 20, 2008 by and between Licensor and Avecia Biologics Limited (the "Amended Agreement");
D. With the consent of the Licensor, Avecia Biologics Limited assigned the Amended Agreement to the Licensee; and
E. The Licensor and the Licensee desire to amend and restate the Amended Agreement.
NOW IT IS HEREBY AGREED BETWEEN THE PARTIES AS FOLLOWS:-
1. DEFINITIONS AND INTERPRETATION
1.1. For the purposes of this Agreement, unless the context clearly or necessarily indicates otherwise, the following words and phrases shall have the meanings set forth below:
1.1.1. "Agreement" shall mean this Amended and Restated Agreement.
1.1.2. "[***] Vaccine" shall mean [***] which is produced using recombinant technology.
1.1.3. "[***] Vaccine Dose" shall mean the quantity of a formulation containing [***] Vaccine given to an individual in a single immunisation.
1.1.4. "Commencement Date" shall mean the day and year first above written.
1.1.5. "The Intellectual Property" shall mean the Patents and know-how, technical information and materials (including but not limited to cell lines) owned by the Licensor necessary or useful to develop,
PRIVATE BETWEEN THE PARTIES
manufacture, have manufactured, import use, keep, sell and offer to sell the [***] Vaccine and the [***] Vaccine Dose.
1.1.6. "Licensed Product" shall mean [***] Vaccine Dose the manufacture, use, sale, keeping, importing or exporting of which would, in the absence of the licence granted under this Agreement, constitute an infringement of the Patents (for the avoidance of doubt, where the definition of Patents includes pending patent applications, this includes doing anything in respect of a claim in a pending patent application that had a patent been granted on such a claim would constitute infringement of that claim) or that uses other Intellectual Property.
1.1.7. "Net Sales Price" shall mean the actual sale price for Licensed Product invoiced by the Licensee or, where applicable, a Partner of the Licensee less any separate charges identified for packaging, transportation, insurance and sales taxes and (where applicable) any royalties paid to any Third Party in respect of the Licensed Product in question. If the Licensee sells or disposes of any Licensed Product on otherwise than an arms length transaction basis at the open full market price (eg to another company in the Licensee92s group or under an off-set or barter agreement), the open market price shall be taken as the actual sales price.
1.1.8. "PIL" shall mean [***].
1.1.9. "Patents" The patents and patent applications set out in Schedule 1 and any equivalents thereof, and any divisionals, continuations, continuations-in-part, re-filings or re-issues of any of the foregoing, and any other patent applications or patents that would be infringed by manufacture, use or sale of an [***] Vaccine or component thereof.
1.1.10. "Partner" shall mean any Third Party organisation which the Licensee elects to involve in the performance of a Supply Contract.
1.1.11. "Third Party" shall mean any person other than the Government of the United Kingdom.
1.2. The singular shall include the plural and vice versa, and the masculine shall include the feminine or the neuter gender and vice versa.
1.3. Unless the context otherwise indicates, references to Articles and Articles and Schedule, are to articles and Articles and the Schedule of this Agreement.
1.4. Headings to Articles in this Agreement are included for ease of reference only and shall not have any effect on the construction or the interpretation of this Agreement.
1.5. References in this Agreement to any statute or statutory provision shall include any statute or statutory provision which amends, extends, consolidates or replaces the same and shall include any orders, regulations, instruments or other subordinate legislation made under the relevant statute.
PRIVATE BETWEEN THE PARTIES
2. GRANT OF RIGHTS BY THE LICENSOR
2.1. In consideration for the payments to be made by the Licensee to the Licensor under the provisions of Article 3 below, the Licensor, warranting that he has the right to do so, hereby grants and the Licensee hereby accepts a nonexclusive worldwide licence to use the Intellectual Property (i) to develop, make, or have made, use, keep, sell, offer to sell, import and export Licensed Products, and (ii) to develop, make, have made, and use [***] Vaccine for the purpose of Licensor exercising the rights and licenses granted to Licensor with respect to Licensed Product.
2.2. Without prejudice to the provisions of Articles 2.3 and 10.3 below, the Licensor undertakes that it shall not whilst this license remains in effect grant a license to any third party for under the Intellectual Property to make, have made, use, keep, import, export, sell or offer to sell Licensed Products or [***] Vaccine.
2.3. For the avoidance of any doubt, the Licensor and any other Department or Agency of the UK Government shall retain the right at any time to use, or authorise others to use the Licensed Products for any UK Government purpose or otherwise to the extent customary pursuant to standard UK Ministry of Defence contracting procedures, and to dispose of products made in consequence of such use but no longer required; and nothing in this Agreement shall be construed as in any way limiting or derogating from such retained rights, nor from any rights of the Crown arising under any other agreement or contract or provision of law.
2.4. Save as permitted under Article 2.5 below, the licence granted under this Agreement is personal to the Licensee and as such shall not be assigned, sub-licensed, mortgaged or in any way dealt with by the Licensee without the prior written consent of the Licensor, which consent shall not be unreasonably withheld, provided that the Licensee may assign the licence and this Agreement without consent in connection with a genuine business reorganisation or to any corporation, association or other business entity which directly or indirectly controls, is controlled by or is under common control with the Licensee. For the avoidance of doubt, consent shall be deemed to be reasonably withheld where the Chief Executive of Dstl receives written notice from an appropriate authority at the Ministry of Defence or other UK Government Department that assignment to such person would damage the essential public or national interest. Any assignment, sub-licensing or mortgaging of this Agreement by the Licensee, otherwise than as permitted by this Article 2.4, without the prior written consent of the Licensor shall immediately invalidate this Agreement and the license granted hereunder.
2.5. Notwithstanding the provisions of Article 2.4 above, the Licensee shall be entitled to employ Partners to assist the Licensee in exercising the Licensee92s rights hereunder with respect to Licensed Products subject to the provisions of Article 3 below.
2.6. Save as expressly stated under this Article 2 the Licensee is not authorised hereunder to grant to any Third Party any sub-license under the Patents or to pass to such Third Party any of the Intellectual Property.
PRIVATE BETWEEN THE PARTIES
3. LICENCE PAYMENTS
3.1. In consideration for the grant of rights by the Licensor in Article 2.1 above; the Licensee shall pay to the Licensor a royalty on each and every Licensed Product, equal to [***] of the Net Sales Price of the Licensed Product. Notwithstanding the foregoing, no royalties shall be payable in respect of any samples of Licensed Products which are provided by the Licensee for clinical, product development, marketing development or bona fide study purposes. No royalties are payable in respect of supplies of Licensed Products to the UK Ministry of Defence.
3.2. The royalty in respect of a Licensed Product shall become payable by the Licensee under this Agreement when the cost of the Licensed Product is invoiced by Licensee. Where the cost of a Licensed Product is payable in two or more installments, the invoice for each installment will be considered separately for the payment of royalties. If no invoice is issued, royalty will become due on delivery of the Licensed Product concerned.
3.3. The Licensee shall reimburse Licensor for the cost and expense incurred by Licensor after the date of this Agreement for prosecuting and maintaining Patents licensed to Licensee under this Agreement. Should the Licensor wish to abandon a patent, patent application or equivalent forming part of the Intellectual Property, it shall offer it to the Licensee, which shall be entitled to maintain in force the said patent, patent application or equivalent in the name of Licensor at the Licensee92s expense but otherwise without charge and, the Licensee shall be responsible for all further expenditure thereon. The Licensee shall retain a royalty free non-exclusive license thereto pursuant to Section 2.1 that is subject to Licensor92s obligations under Section 2.2.
3.4. The payments due under Articles 3.1 and 3.3 of this Agreement will fall due half-yearly on 30 June and 31 December and will be payable in accordance with the instructions contained in Articles 3.6 and 3.7 below.
3.5. The Licensor has appointed PIL as its agent to act on its behalf for the administration of royalties and other moneys due under this Agreement. .
3.6. Within sixty (60) days of the end of each half-year period as mentioned in Article 3.4 hereof, the Licensee shall send to PIL (or as otherwise advised) a true and complete statement in writing, including where appropriate a Zero return, of the number of Licensed Products manufactured and sold by or for Licensee during the relevant period, the Net Sales Price derived from sales of such Licensed Products, and the royalty calculated to be payable in respect thereof in accordance with the provisions of Article 3.1.
3.7. All payments due to the Licensor under this Agreement shall be made by the end of the month following the month of the date of receipt of an invoice from PIL and in accordance with the instructions issued with the relevant invoice. All royalty statements, correspondence and payments to PIL under the provisions of this Article 3 shall quote the PIL reference [***].
3.8. All payments due to PIL shall be paid in pounds Sterling plus, if applicable, VAT at the UK rate prevailing at the time of payment. Where a payment due is in a currency other than pounds Sterling, the rate of exchange to be applied shall be the rate of exchange applied by the Bank of England on the d ...
*End of Preview*
Click the 'Add to Cart' button to download the complete and formatted agreement.
Agreement#: AG-658261
Pages: 51 pages
Format: MS Word Compatible
Price: $35.00
Add To Cart View other agreements from Pharmathene, Inc. agreements
Healthcare Acquisition - Promissory Note
Healthcare Acquisition - Investment Management Agreement
. Privacy Policy Terms of Service
© Copyright TechAgreements L.L.C. 2007
und noch was:
Nexia Biotechnologies wollte aus Ziegenmilch Spinnenseide gewinnen, die dann in der Chirurgie oder in kugelsicheren Westen eingesetzt werden sollte.
Nexia ist inzwischen von PharmAthene aufgekauft. PharmAthene will auf ähnliche Weise die Mittel gegen Nervengas in die Produktion nehmen. Eine Zellkultur-Fabrik kostet Millionen von Dollar - Ziegen auf der Wiese deutlich weniger. (Forbes, 09.02.09; New York Times
As the co-chair of Edwards Angell Palmer & Dodge's Private Equity & Venture Capital Group, Jim Barrett is a business and securities lawyer who represents life sciences and other technology companies as well as venture capital and private equity funds. He regularly counsels Boards of Directors and General Partners on corporate governance matters and guides their businesses through all stages of development. Accordingly, Jim concentrates in investment transactions, mergers and acquisitions, securities law and general corporate representation.
The sale of PharmAthene to Healthcare Acquisition Corp., in which we represented Bear Stearns Health Innoventures, HealthCare Ventures and MPM Capital as the major stockholders of PharmAthene. We had previously represented such investors in a $50 million financing of PharmAthene
... Protecting the nation from catastrophic bioterrorist health emergencies – the biosecurity industry press release, March 18 2009
David P. Wright, Co-Chair of the Alliance for Biosecurity and Chairman and CEO of PharmAthene, Inc., testified today before the House Labor, Health and Human Services, and Education Appropriations Subcommittee on the critical importance of developing drugs, vaccines and other medical countermeasures needed to protect Americans from bioterrorism and other catastrophic health emergencies. Effective medical countermeasures for many of the chemical, biological, radiological, and nuclear (CBRN) agents that pose the greatest threat to the United States do not currently exist, and Wright argued that the federal government should take a more active role in supporting their development to bolster the nation’s biosecurity.
GOOD!
.....
Nexia Biotechnologies wollte aus Ziegenmilch Spinnenseide gewinnen, die dann in der Chirurgie oder in kugelsicheren Westen eingesetzt werden sollte.
Nexia ist inzwischen von PharmAthene aufgekauft. PharmAthene will auf ähnliche Weise die Mittel gegen Nervengas in die Produktion nehmen. Eine Zellkultur-Fabrik kostet Millionen von Dollar - Ziegen auf der Wiese deutlich weniger. (Forbes, 09.02.09; New York Times
As the co-chair of Edwards Angell Palmer & Dodge's Private Equity & Venture Capital Group, Jim Barrett is a business and securities lawyer who represents life sciences and other technology companies as well as venture capital and private equity funds. He regularly counsels Boards of Directors and General Partners on corporate governance matters and guides their businesses through all stages of development. Accordingly, Jim concentrates in investment transactions, mergers and acquisitions, securities law and general corporate representation.
The sale of PharmAthene to Healthcare Acquisition Corp., in which we represented Bear Stearns Health Innoventures, HealthCare Ventures and MPM Capital as the major stockholders of PharmAthene. We had previously represented such investors in a $50 million financing of PharmAthene
... Protecting the nation from catastrophic bioterrorist health emergencies – the biosecurity industry press release, March 18 2009
David P. Wright, Co-Chair of the Alliance for Biosecurity and Chairman and CEO of PharmAthene, Inc., testified today before the House Labor, Health and Human Services, and Education Appropriations Subcommittee on the critical importance of developing drugs, vaccines and other medical countermeasures needed to protect Americans from bioterrorism and other catastrophic health emergencies. Effective medical countermeasures for many of the chemical, biological, radiological, and nuclear (CBRN) agents that pose the greatest threat to the United States do not currently exist, and Wright argued that the federal government should take a more active role in supporting their development to bolster the nation’s biosecurity.
GOOD!
.....
PharmAthene Presents Data for Valortim(R) Anthrax Anti-Toxin and Third Generation...
Thu Sep 3, 2009 8:54am EDT
PharmAthene Presents Data for Valortim(R) Anthrax Anti-Toxin and Third
Generation rPA Anthrax Vaccine Programs at the Bacillus - ACT 2009 Conference
ANNAPOLIS, Md., Sept. 3 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (NYSE
Amex: PIP), a biodefense company developing medical countermeasures against
biological and chemical threats, announced today that data from the Company's
third generation recombinant protective antigen (rPA) anthrax vaccine program
and its Valortim((R)) anthrax anti-toxin program were presented at the
Bacillus - ACT 2009 meeting, August 30 - September 3, 2009, organized by the
American Society for Microbiology.
David P. Wright, President and Chief Executive Officer of PharmAthene
commented, "Preliminary data from our third generation (3G) rPA anthrax
vaccine program suggest that a 3G product prototype may be able to provide a
more rapid onset of immunity and enhanced immunogenicity than the currently
available anthrax vaccine, suggesting the potential for a vaccine that can be
given in fewer doses than is required today."
"Additionally, new data from our Valortim((R)) program were presented
highlighting the potential for Valortim((R)) as a promising new therapeutic
for anthrax. In the African Green Monkey (AGM) model, up to 70% of
Valortim((R))-treated animals survived inhalational challenge with anthrax
spores. A second poster, presented additional studies in immunodeficient
mouse models, and demonstrated the unique activity of Valortim((R)) in
protecting these mice from being killed by B. anthracis. These data suggest a
potential unique mechanism of action for Valortim(TM) that will need to be
substantiated in additional studies," continued Mr. Wright.
Valortim((R)), which is being co-developed by PharmAthene and Medarex, Inc.,
is a fully human monoclonal antibody designed to protect against and treat
inhalational anthrax, the most lethal form of illness in humans caused by
anthrax.
Zwischenzeitlich stieg der Kurs um 13-14%, jetzt "nur" noch um 7 %
Thu Sep 3, 2009 8:54am EDT
PharmAthene Presents Data for Valortim(R) Anthrax Anti-Toxin and Third
Generation rPA Anthrax Vaccine Programs at the Bacillus - ACT 2009 Conference
ANNAPOLIS, Md., Sept. 3 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (NYSE
Amex: PIP), a biodefense company developing medical countermeasures against
biological and chemical threats, announced today that data from the Company's
third generation recombinant protective antigen (rPA) anthrax vaccine program
and its Valortim((R)) anthrax anti-toxin program were presented at the
Bacillus - ACT 2009 meeting, August 30 - September 3, 2009, organized by the
American Society for Microbiology.
David P. Wright, President and Chief Executive Officer of PharmAthene
commented, "Preliminary data from our third generation (3G) rPA anthrax
vaccine program suggest that a 3G product prototype may be able to provide a
more rapid onset of immunity and enhanced immunogenicity than the currently
available anthrax vaccine, suggesting the potential for a vaccine that can be
given in fewer doses than is required today."
"Additionally, new data from our Valortim((R)) program were presented
highlighting the potential for Valortim((R)) as a promising new therapeutic
for anthrax. In the African Green Monkey (AGM) model, up to 70% of
Valortim((R))-treated animals survived inhalational challenge with anthrax
spores. A second poster, presented additional studies in immunodeficient
mouse models, and demonstrated the unique activity of Valortim((R)) in
protecting these mice from being killed by B. anthracis. These data suggest a
potential unique mechanism of action for Valortim(TM) that will need to be
substantiated in additional studies," continued Mr. Wright.
Valortim((R)), which is being co-developed by PharmAthene and Medarex, Inc.,
is a fully human monoclonal antibody designed to protect against and treat
inhalational anthrax, the most lethal form of illness in humans caused by
anthrax.
Zwischenzeitlich stieg der Kurs um 13-14%, jetzt "nur" noch um 7 %
und weiter gehts ab, leider hatte ich in der kurzen Schwäche vor 2 Tagen Tagen kein Geld zum Nachkaufen
dass ich hier immer noch allein bin?? Den nächsten größeren Rücksetzer nutze ich. Wenn sie noch mal unter 3,90 fällt
Antwort auf Beitrag Nr.: 37.941.072 von dottore am 08.09.09 19:38:57in USA steigen die Umsätze an. Jetzt schon mehr Stücke gehandelt als gestern bei weiter steigendem Kurs.
Hier kommt was richtig großes! 3,90 wird es wohl nicht wieder geben
Hier kommt was richtig großes! 3,90 wird es wohl nicht wieder geben
ich wollte ja schon nachlegen, wenn der Kurs unter 3,90 fällt, habe mich aber zurückgehalten und erst jetzt bei 3,60 noch einmal zugelangt.
6 Teilausführungen, so ein scheiß - was wieder kostet?!
Aber ich bin von dem Wert 100 pro überzeugt. Dieser tiefe Rücksetzer gefällt mir. Leider habe ich den Hype bei 4,20 verpasst. Beim nächsten Hype schmeiße ich dann auch mal einen Teil um dann später wieder eine Welle mitzunehmen etc
6 Teilausführungen, so ein scheiß - was wieder kostet?!
Aber ich bin von dem Wert 100 pro überzeugt. Dieser tiefe Rücksetzer gefällt mir. Leider habe ich den Hype bei 4,20 verpasst. Beim nächsten Hype schmeiße ich dann auch mal einen Teil um dann später wieder eine Welle mitzunehmen etc
diese Nachricht könnte einen kleien Hype bringen, schließlich wird so im Umfeld der US-Regierung wieder einaml auf sich aufmerksam gemacht und das Management hat erstklassige connections
PharmAthene Executives Featured in Anthrax Pathogen Training Video for U.S. Department of Homeland Security
ANNAPOLIS, Md., Oct. 5 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, today announced that company President and Chief Executive Officer, David P. Wright and Dr. Valerie Riddle, Vice President and Medical Director, were featured in the Homeland Security Television Channel (HSTV) 30-minute documentary training video entitled, "Deadly Pathogen: Exploring the Anthrax Threat," which was distributed to 65,000 members of the U.S. Department of Homeland Security.
The HSTV Deadly Pathogen documentary video provides an in-depth analysis of the biological agent, Bacillus Anthracis, the bacteria that causes anthrax, and details what this deadly pathogen does to the human body and why it remains such an imminent threat to the security of millions of people worldwide.
The training video was broadcast on the HSTV Threat Matrix Show that investigates current trends and issues in Homeland Security. The show takes an investigative approach to the policy and technology challenges and emerging threats facing the homeland security community.
"We are delighted to share our expertise with the U.S. Department of Homeland Security on anthrax weaponization, anthrax disease pathogenesis, and promising, second generation vaccine product candidates to address this biological threat," commented David P. Wright. "PharmAthene is developing a second generation recombinant protective antigen (rPA) anthrax vaccine called SparVax(TM) to protect civilians and the military and to advance our company goal of becoming the leading provider of best-in-class medical countermeasures for the biodefense industry."
The HSTV Deadly Pathogen: Exploring the Anthrax Threat 30-minute documentary video can be viewed on the link below.
http://www.hstvchannel.com/ThreatMatrix/Deadly_Pathogen_Anthrax.html" target="_blank" rel="nofollow ugc noopener">http://www.hstvchannel.com/ThreatMatrix/Deadly_Pathogen_Anthrax.html
Homeland Security Television Channel
The Homeland Security Television Channel (HSTV) is the world's first online, on-demand television network dedicated to homeland security and global development. HSTV is a 24/7 interactive television channel dedicated to producing broadcast-quality video programs on all aspects of homeland security and the role of global development in fighting terrorism. http://www.hstvchannel.com
About PharmAthene, Inc.
PharmAthene was formed to meet the critical needs of the United States and its allies by developing and commercializing medical countermeasures against biological and chemical weapons. PharmAthene's lead product development programs include:
•SparVax(TM) - a second generation recombinant protective antigen (rPA) anthrax vaccine
•Third generation rPA anthrax vaccine
•Valortim® - a fully human monoclonal antibody for the prevention and treatment of anthrax infection
•Protexia® - a novel bioscavenger for the prevention and treatment of morbidity and mortality associated with exposure to chemical nerve agents
For more information about PharmAthene, please visit www.PharmAthene.com.
PharmAthene Executives Featured in Anthrax Pathogen Training Video for U.S. Department of Homeland Security
ANNAPOLIS, Md., Oct. 5 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, today announced that company President and Chief Executive Officer, David P. Wright and Dr. Valerie Riddle, Vice President and Medical Director, were featured in the Homeland Security Television Channel (HSTV) 30-minute documentary training video entitled, "Deadly Pathogen: Exploring the Anthrax Threat," which was distributed to 65,000 members of the U.S. Department of Homeland Security.
The HSTV Deadly Pathogen documentary video provides an in-depth analysis of the biological agent, Bacillus Anthracis, the bacteria that causes anthrax, and details what this deadly pathogen does to the human body and why it remains such an imminent threat to the security of millions of people worldwide.
The training video was broadcast on the HSTV Threat Matrix Show that investigates current trends and issues in Homeland Security. The show takes an investigative approach to the policy and technology challenges and emerging threats facing the homeland security community.
"We are delighted to share our expertise with the U.S. Department of Homeland Security on anthrax weaponization, anthrax disease pathogenesis, and promising, second generation vaccine product candidates to address this biological threat," commented David P. Wright. "PharmAthene is developing a second generation recombinant protective antigen (rPA) anthrax vaccine called SparVax(TM) to protect civilians and the military and to advance our company goal of becoming the leading provider of best-in-class medical countermeasures for the biodefense industry."
The HSTV Deadly Pathogen: Exploring the Anthrax Threat 30-minute documentary video can be viewed on the link below.
http://www.hstvchannel.com/ThreatMatrix/Deadly_Pathogen_Anthrax.html" target="_blank" rel="nofollow ugc noopener">http://www.hstvchannel.com/ThreatMatrix/Deadly_Pathogen_Anthrax.html
Homeland Security Television Channel
The Homeland Security Television Channel (HSTV) is the world's first online, on-demand television network dedicated to homeland security and global development. HSTV is a 24/7 interactive television channel dedicated to producing broadcast-quality video programs on all aspects of homeland security and the role of global development in fighting terrorism. http://www.hstvchannel.com
About PharmAthene, Inc.
PharmAthene was formed to meet the critical needs of the United States and its allies by developing and commercializing medical countermeasures against biological and chemical weapons. PharmAthene's lead product development programs include:
•SparVax(TM) - a second generation recombinant protective antigen (rPA) anthrax vaccine
•Third generation rPA anthrax vaccine
•Valortim® - a fully human monoclonal antibody for the prevention and treatment of anthrax infection
•Protexia® - a novel bioscavenger for the prevention and treatment of morbidity and mortality associated with exposure to chemical nerve agents
For more information about PharmAthene, please visit www.PharmAthene.com.
New Data Shows PharmAthene's Lyophilized rPA Anthrax Vaccine Could Provide a Stable Cold-Chain-Free Vaccine for Potential Storage and Distribution at Room Temperature
ANNAPOLIS, Md., Dec. 4 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced today the presentation of new data from the Company's anthrax vaccine program showing that its lyophilized recombinant Protective Antigen (rPA) based anthrax vaccine is structurally stable and potent after 16 months at various temperatures up to and including 55 degrees C. The data were presented by Dr. Matthew Duchars, Chief Scientific Officer for PharmAthene, during an oral session at the HHS Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) Stakeholders Workshop 2009 / BARDA Industry Day.
David P. Wright, President and Chief Executive Officer of PharmAthene, commented, "These new data are very encouraging as they demonstrate that PharmAthene's lyophilized rPA could be used to provide a stable cold-chain-free vaccine, enabling us to develop a formulation which could be stored and distributed at room temperature, an important attribute for deployment in the civilian Strategic National Stockpile."
Next Generation Anthrax Vaccines
Various government agencies, including the Institute of Medicine, have acknowledged the urgent need to stockpile next-generation anthrax vaccines employing modern vaccine technology, which offer the potential for improved safety, convenience and more rapid immunity, ideally with a potential to provide protective immunity in sixty days compared to six months for the currently licensed anthrax vaccine.
As a result of this Federal requirement, a Request for Proposals (RFP) was issued by the Biomedical Advanced Research and Development Authority (BARDA) for the acquisition of 25 million doses of rPA anthrax vaccine for the Strategic National Stockpile. The Company's second generation rPA anthrax vaccine, SparVax(TM), is currently under consideration for a major advanced development and procurement contract through BARDA.
PharmAthene's portfolio includes second generation and third generation rPA anthrax vaccine product candidates, which incorporate significant product development and technological advancements and are designed to meet these requirements.
The goal of PharmAthene's third generation rPA vaccine program is to develop a vaccine formulation which can induce a more rapid onset of protective immunity in fewer doses, and can be stored, transported and used without the need for a conventional cold chain -- an important advantage for civilian biodefense deployment within the Strategic National Stockpile.
Summary of the Data Presented
In an oral presentation entitled, "Development of a Highly Stable Lyophilized rPA-Based Anthrax Vaccine," Dr. Duchars presented results from a series of studies evaluating different approaches to increase the stability of an rPA anthrax vaccine product candidate. Of the techniques evaluated, lyophilization showed exceptional stability. An optimized lyophilized formulation of rPA was subsequently tested in an accelerated stability study at 5 degrees C; 25 degrees C; 40 degrees C; and 55 degrees C.
At 3 months, little evidence of rPA degradation was detected in the samples at all temperatures up to and including 55 degrees C. Using the mouse challenge assay, the lyophilized rPA vaccine was shown to have retained potency. Subsequent analysis at 16 months demonstrated that the rPA had retained both structural integrity and vaccine potency.
These preliminary data suggest that an optimized rPA formulation could be used to provide a stable cold-chain-free vaccine. Scale-up of the lyophilization process is currently underway.
Funding for these studies was provided under a Challenge grant (UC1 AI067223-01) from the National Institutes of Health.
About Anthrax
According to the Centers for Disease Control and Prevention, anthrax is an acute infectious disease caused by the spore-forming bacterium Bacillus anthracis. Anthrax most commonly occurs in hoofed mammals and can also infect humans. Symptoms of disease vary depending on how the disease is contracted, but usually occur within seven days after exposure. The serious forms of human anthrax are inhalation anthrax, cutaneous anthrax, and intestinal anthrax. Initial symptoms of inhalation anthrax infection may resemble a common cold. After several days, the symptoms may progress to severe breathing problems and shock. Inhalation anthrax is often fatal, even if treated by antibiotics. Currently, antibiotics are the only drugs available for therapeutic or prophylactic use for inhalation anthrax, and post-exposure prophylaxis is the only FDA-approved indication for such products. However, antibiotic therapy, while useful, is believed to be associated with a number of limitations, including: (1) lack of activity against the toxins produced by the B. anthracis bacteria, (2) need for long-term dosing to achieve full protection, complicated by side effects and non-compliance, (3) lack of efficacy when administered late in the anthrax disease cycle, and (4) lack of effectiveness against multi-drug resistant or genetically engineered strains of anthrax.
About PharmAthene, Inc.
PharmAthene was formed to meet the critical needs of the United States and its allies by developing and commercializing medical countermeasures against biological and chemical weapons. PharmAthene's lead product development programs include:
-- SparVax(TM) -- a second generation recombinant protective antigen (rPA) anthrax vaccine -- Third generation rPA anthrax vaccine -- Valortim® -- a fully human monoclonal antibody for the prevention and treatment of anthrax infection -- Protexia® -- a novel bioscavenger for the prevention and treatment of morbidity and mortality associated with exposure to chemical nerve agents -- RypVax(TM) -- a recombinant dual antigen vaccine for plague
For more information about PharmAthene, please visit http://www.pharmathene.com/." target="_blank" rel="nofollow ugc noopener">http://www.pharmathene.com/.
Statement on Cautionary Factors
Except for the historical information presented herein, matters discussed may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Statements that are not historical facts, including statements preceded by, followed by, or that include the words "potential"; "believe"; "anticipate"; "intend"; "plan"; "expect"; "estimate"; "could"; "may"; "should"; or similar statements are forward-looking statements. PharmAthene disclaims, however, any intent or obligation to update these forward-looking statements. Risks and uncertainties include risk associated with the reliability of the results of the studies relating to human safety and possible adverse effects resulting from the administration of the Company's product candidates, unexpected funding delays and/or reductions or elimination of U.S. government funding for one or more of the Company's development programs, including without limitation our bid related to SparVax(TM) under the HHS Request for Proposals for an Anthrax Recombinant Protective Antigen (rPA) Vaccine for the Strategic National Stockpile, the award of government contracts to our competitors, unforeseen safety issues, challenges related to the development, scale-up, and/or process validation of manufacturing processes for our product candidates, unexpected determinations that these product candidates prove not to be effective and/or capable of being marketed as products, unexpected financial obligations that could increase the rate of our cash consumption, as well as risks detailed from time to time in PharmAthene's Forms 10-K and 10-Q under the caption "Risk Factors" and in its other reports filed with the U.S. Securities and Exchange Commission (the "SEC"). In particular, significant additional research work, non-clinical animal studies, human clinical trials, and manufacturing development work remain to be completed for the Company's lyophilized 3G rPA anthrax vaccine candidate. At this point there can be no assurance that this product candidate will be shown to be safe and effective and approved by regulatory authorities for use in humans. Copies of PharmAthene's public disclosure filings are available from its investor relations department and our website under the investor relations tab at http://www.pharmathene.com/." target="_blank" rel="nofollow ugc noopener">http://www.pharmathene.com/.
DATASOURCE: PharmAthene, Inc.
CONTACT: Stacey Jurchison of PharmAthene, Inc., +1-410-269-2610,
Web Site: http://www.pharmathene.com/
ANNAPOLIS, Md., Dec. 4 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced today the presentation of new data from the Company's anthrax vaccine program showing that its lyophilized recombinant Protective Antigen (rPA) based anthrax vaccine is structurally stable and potent after 16 months at various temperatures up to and including 55 degrees C. The data were presented by Dr. Matthew Duchars, Chief Scientific Officer for PharmAthene, during an oral session at the HHS Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) Stakeholders Workshop 2009 / BARDA Industry Day.
David P. Wright, President and Chief Executive Officer of PharmAthene, commented, "These new data are very encouraging as they demonstrate that PharmAthene's lyophilized rPA could be used to provide a stable cold-chain-free vaccine, enabling us to develop a formulation which could be stored and distributed at room temperature, an important attribute for deployment in the civilian Strategic National Stockpile."
Next Generation Anthrax Vaccines
Various government agencies, including the Institute of Medicine, have acknowledged the urgent need to stockpile next-generation anthrax vaccines employing modern vaccine technology, which offer the potential for improved safety, convenience and more rapid immunity, ideally with a potential to provide protective immunity in sixty days compared to six months for the currently licensed anthrax vaccine.
As a result of this Federal requirement, a Request for Proposals (RFP) was issued by the Biomedical Advanced Research and Development Authority (BARDA) for the acquisition of 25 million doses of rPA anthrax vaccine for the Strategic National Stockpile. The Company's second generation rPA anthrax vaccine, SparVax(TM), is currently under consideration for a major advanced development and procurement contract through BARDA.
PharmAthene's portfolio includes second generation and third generation rPA anthrax vaccine product candidates, which incorporate significant product development and technological advancements and are designed to meet these requirements.
The goal of PharmAthene's third generation rPA vaccine program is to develop a vaccine formulation which can induce a more rapid onset of protective immunity in fewer doses, and can be stored, transported and used without the need for a conventional cold chain -- an important advantage for civilian biodefense deployment within the Strategic National Stockpile.
Summary of the Data Presented
In an oral presentation entitled, "Development of a Highly Stable Lyophilized rPA-Based Anthrax Vaccine," Dr. Duchars presented results from a series of studies evaluating different approaches to increase the stability of an rPA anthrax vaccine product candidate. Of the techniques evaluated, lyophilization showed exceptional stability. An optimized lyophilized formulation of rPA was subsequently tested in an accelerated stability study at 5 degrees C; 25 degrees C; 40 degrees C; and 55 degrees C.
At 3 months, little evidence of rPA degradation was detected in the samples at all temperatures up to and including 55 degrees C. Using the mouse challenge assay, the lyophilized rPA vaccine was shown to have retained potency. Subsequent analysis at 16 months demonstrated that the rPA had retained both structural integrity and vaccine potency.
These preliminary data suggest that an optimized rPA formulation could be used to provide a stable cold-chain-free vaccine. Scale-up of the lyophilization process is currently underway.
Funding for these studies was provided under a Challenge grant (UC1 AI067223-01) from the National Institutes of Health.
About Anthrax
According to the Centers for Disease Control and Prevention, anthrax is an acute infectious disease caused by the spore-forming bacterium Bacillus anthracis. Anthrax most commonly occurs in hoofed mammals and can also infect humans. Symptoms of disease vary depending on how the disease is contracted, but usually occur within seven days after exposure. The serious forms of human anthrax are inhalation anthrax, cutaneous anthrax, and intestinal anthrax. Initial symptoms of inhalation anthrax infection may resemble a common cold. After several days, the symptoms may progress to severe breathing problems and shock. Inhalation anthrax is often fatal, even if treated by antibiotics. Currently, antibiotics are the only drugs available for therapeutic or prophylactic use for inhalation anthrax, and post-exposure prophylaxis is the only FDA-approved indication for such products. However, antibiotic therapy, while useful, is believed to be associated with a number of limitations, including: (1) lack of activity against the toxins produced by the B. anthracis bacteria, (2) need for long-term dosing to achieve full protection, complicated by side effects and non-compliance, (3) lack of efficacy when administered late in the anthrax disease cycle, and (4) lack of effectiveness against multi-drug resistant or genetically engineered strains of anthrax.
About PharmAthene, Inc.
PharmAthene was formed to meet the critical needs of the United States and its allies by developing and commercializing medical countermeasures against biological and chemical weapons. PharmAthene's lead product development programs include:
-- SparVax(TM) -- a second generation recombinant protective antigen (rPA) anthrax vaccine -- Third generation rPA anthrax vaccine -- Valortim® -- a fully human monoclonal antibody for the prevention and treatment of anthrax infection -- Protexia® -- a novel bioscavenger for the prevention and treatment of morbidity and mortality associated with exposure to chemical nerve agents -- RypVax(TM) -- a recombinant dual antigen vaccine for plague
For more information about PharmAthene, please visit http://www.pharmathene.com/." target="_blank" rel="nofollow ugc noopener">http://www.pharmathene.com/.
Statement on Cautionary Factors
Except for the historical information presented herein, matters discussed may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Statements that are not historical facts, including statements preceded by, followed by, or that include the words "potential"; "believe"; "anticipate"; "intend"; "plan"; "expect"; "estimate"; "could"; "may"; "should"; or similar statements are forward-looking statements. PharmAthene disclaims, however, any intent or obligation to update these forward-looking statements. Risks and uncertainties include risk associated with the reliability of the results of the studies relating to human safety and possible adverse effects resulting from the administration of the Company's product candidates, unexpected funding delays and/or reductions or elimination of U.S. government funding for one or more of the Company's development programs, including without limitation our bid related to SparVax(TM) under the HHS Request for Proposals for an Anthrax Recombinant Protective Antigen (rPA) Vaccine for the Strategic National Stockpile, the award of government contracts to our competitors, unforeseen safety issues, challenges related to the development, scale-up, and/or process validation of manufacturing processes for our product candidates, unexpected determinations that these product candidates prove not to be effective and/or capable of being marketed as products, unexpected financial obligations that could increase the rate of our cash consumption, as well as risks detailed from time to time in PharmAthene's Forms 10-K and 10-Q under the caption "Risk Factors" and in its other reports filed with the U.S. Securities and Exchange Commission (the "SEC"). In particular, significant additional research work, non-clinical animal studies, human clinical trials, and manufacturing development work remain to be completed for the Company's lyophilized 3G rPA anthrax vaccine candidate. At this point there can be no assurance that this product candidate will be shown to be safe and effective and approved by regulatory authorities for use in humans. Copies of PharmAthene's public disclosure filings are available from its investor relations department and our website under the investor relations tab at http://www.pharmathene.com/." target="_blank" rel="nofollow ugc noopener">http://www.pharmathene.com/.
DATASOURCE: PharmAthene, Inc.
CONTACT: Stacey Jurchison of PharmAthene, Inc., +1-410-269-2610,
Web Site: http://www.pharmathene.com/
Was ist denn passiert?
Gruß, greenhorn
Antwort auf Beitrag Nr.: 38.541.998 von greenhorn1998 am 10.12.09 11:00:37PharmAthene, Inc.: BARDA Announces Modification to Development Approach for Recombinant Protective Antigen Anthrax Vaccines; Original Request Has Been Axed
12/9/2009
http://www.biospace.com/news_story.aspx?NewsEntityId=164935
Nur ein kleiner Rückschlag, wie er im Biotech-Bereich häufiger vorkommt. Es bleibt dennoch intereesant, diesen Wert zu beobachten.
12/9/2009
http://www.biospace.com/news_story.aspx?NewsEntityId=164935
Nur ein kleiner Rückschlag, wie er im Biotech-Bereich häufiger vorkommt. Es bleibt dennoch intereesant, diesen Wert zu beobachten.
wie weiter oben angekündigt, hatte ich den größten Teil mit etwa 4 $ verkauft und nur 600 Stück behalten.
Mit denen, die habe ich zu 3,60 nachgekauft, bin ich jetzt doch heftig im Minus. Kurzfristig erwarte ich hier keine großen Ausschläge mehr, vielleicht ab September 2010, Dann verbillige ich ....
Mit denen, die habe ich zu 3,60 nachgekauft, bin ich jetzt doch heftig im Minus. Kurzfristig erwarte ich hier keine großen Ausschläge mehr, vielleicht ab September 2010, Dann verbillige ich ....
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Investoren beobachten auch:
| Wertpapier | Perf. % |
|---|---|
| -2,90 | |
| +1,02 | |
| -9,92 | |
| -1,15 | |
| +5,80 | |
| +0,54 | |
| -2,00 | |
| -1,88 | |
| -1,85 | |
| -1,09 |
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 183 | ||
| 98 | ||
| 70 | ||
| 65 | ||
| 42 | ||
| 40 | ||
| 37 | ||
| 34 | ||
| 33 | ||
| 33 |
